A Framework for Developing Pharmacotherapy for Agitation in Alzheimer's disease: Recommendations of the ISCTM Working Group
1. Axsome Therapeutics Inc. New York, NY, USA; 2. Department of Psychiatry and Behavioral Neuroscience, Saint Louis University School of Medicine, MO, USA; 3. Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA; 4. Pfizer Inc. Collegeville, PA, USA; 5. Leoben Research srl, Rome, Italy; 6. Avanir Pharmaceuticals Inc. Aliso Viejo, CA, USA; 7. Follow the Molecule LLC and Alliance for Early Phase, Marina del Rey, CA, USA; 8. H. Lundbeck A/S, Valby, Denmark; 9. moebius consult GmbH, Baar, Switzerland; 10. California Neuroscience Research Medical Group Inc./CTSdatabase LLC. Sherman Oaks, CA, USA; 11. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. *ISCTM: International Society for CNS Clinical Trials and Methodology.
The Journal of Prevention of Alzheimer's Disease